Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112157 | 0.80 | LMNA (0.58) | LTA4HLMNAMEN1KMT2ACCR9 | |
| SCHEMBL2947698 | 0.80 | LTA4H (0.33) | LTA4HLMNANAPRTRAB9ANPC1 | |
| SCHEMBL8801902 | 0.79 | LTA4H (0.61) | LTA4HLMNAMEN1KMT2ANAPRT | |
| SCHEMBL2943450 | 0.78 | KMT2A (0.36) | LTA4HLMNAKMT2ARAB9ANPC1 | |
| SCHEMBL2943447 | 0.78 | KMT2A (0.36) | LTA4HLMNAKMT2ARAB9ANPC1 | |
| SCHEMBL14015806 | 0.78 | LTA4H (0.46) | LTA4HLMNAMEN1KMT2ANAPRT | |
| SCHEMBL2946859 | 0.76 | MTOR (0.40) | LMNAMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL9037143 | 0.76 | LTA4H (0.61) | LTA4HLMNAMEN1KMT2ANAPRT | |
| SCHEMBL343289 | 0.75 | LTA4H (0.50) | LTA4HLMNAMEN1KMT2ANAPRT | |
| SCHEMBL2943438 | 0.74 | IDO1 (0.48) | LMNANAPRTRAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750026-B2 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750026-B2 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750026-B2 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1709028-B1 | FUSED HETEROARYL DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20070054942-A1 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054942-A1 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054942-A1 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2007-03-08 | — | — | US | disclosed |
| EP-1709028-A1 | FUSED HETEROARYL DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073217-A1 | FUSED HETEROARYL DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054942-A1 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | MAPK1, MAPK7, MAPKAPK2 | LTA4H 2619/4885LMNA 2780/4885MEN1 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.